It remains an investigational medicinal product (IMP) being evaluated in clinical trials
Its essential that once reconstituted and stored, bacteriostatic water is checked regularly for any signs of microbial growth or degradation in order to ensure that the peptide is still viable and safe for use

Tirzepatide for the treatment of adults with Type 2 diabetes: An endocrine perspective, National Library of Medicine (2022) Wegovy (semaglutide): a new weight loss drug for chronic weight management, National Library of Medicine (2022) Tirzepatide versus semaglutide for weight loss in patients with Type 2 diabetes mellitus: A value for money analysis, National Library of Medicine (2023) Wegovy (semaglutide): a new weight loss drug for chronic weight management, Journal of Investigative Medicine (2021) Mounjorno prescribing information, FDA (2022) Fast Track Status, FDA (2018) Priority Review, FDA (2018) FDA approves novel, dual-targeted treatment for type 2 diabetes, FDA (2022) FDA approves new medication for chronic weight management, FDA (2023) FDA approves Lillys Zepbound (tirzepatide) for chronic weight management, a powerful new option for the treatment of obesity or overweight with weight-related medical problems, Eli Lilly & Co
Fix It Log weekly side effects
Regulatory bodies like the European Medicines Agency have explicitly stated that Ozempic is not intended for weight loss, highlighting the tension between patient demand and appropriate medical use
Monitoring for any signs of adverse reactions or injection site complications